- Home
- AGIO vs TIGR Comparison
AGIO vs TIGR Comparison
Compare AGIO & TIGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGIO | TIGR |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AGIO | TIGR |
|---|---|---|
| Price | $27.95 | $8.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $36.63 | $14.20 |
| AVG Volume (30 Days) | 881.5K | ★ 2.8M |
| Earning Date | 02-12-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 328.15 |
| EPS | N/A | ★ 0.82 |
| Revenue | $54,028,000.00 | ★ $489,538,356.00 |
| Revenue This Year | $104.62 | $79.26 |
| Revenue Next Year | $125.15 | $5.17 |
| P/E Ratio | ★ N/A | $9.73 |
| Revenue Growth | 48.03 | ★ 76.50 |
| 52 Week Low | $22.24 | $6.38 |
| 52 Week High | $46.00 | $13.55 |
Technical Indicators
Market Signals| Indicator | AGIO | TIGR |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 38.09 |
| Support Level | $26.05 | $7.80 |
| Resistance Level | $29.93 | $8.65 |
| Average True Range (ATR) | 1.18 | 0.34 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 62.47 | 21.05 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.